reviewed april 2026|next review october 2026|88 physicians psi has verified|144186 published studies
Degarelix
Degarelix is a synthetic decapeptide GnRH antagonist FDA-approved as Firmagon for advanced prostate cancer, providing immediate testosterone suppression without the initial hormonal flare caused by GnRH agonists.
Evidence landscape: 144186 published studies
144,186 published items (inflated by broad GnRH antagonist query). 12 human studies and 162 animal studies indexed. A focused clinical evidence base supporting the FDA-approved prostate cancer indication.
- 12 Human
- 162 Animal
- 26 Reviews
- 143986 Other research
FDA-approved prescription medicine in the United States as Firmagon (degarelix acetate) for treatment of advanced prostate cancer.
Phase III trial demonstrated non-inferiority to leuprolide with castration achieved within 3 days versus 2-4 weeks. No testosterone flare observed.
Injectable GnRH antagonist. Differentiated from GnRH agonists by immediate suppression without flare. The oral GnRH antagonist relugolix (Orgovyx) offers an alternative antagonist approach.
PSI Assessment
When a prostate cancer patient starts standard hormone therapy, testosterone surges before it drops, a pharmacological flare that can worsen bone pain, spinal cord compression, or urinary obstruction. Degarelix, sold as Firmagon, eliminates that flare entirely. It is a GnRH antagonist that directly blocks the receptor instead of overstimulating it, achieving castration-level testosterone within 3 days versus 2-4 weeks with agonists. The Phase III trial demonstrated non-inferiority to leuprolide with the added benefit of immediate suppression.
Castration-level testosterone within 3 days. No flare. The trade-off is injection site reactions in approximately 40% of patients.
The mechanism is direct GnRH receptor blockade. Where GnRH agonists overstimulate and then desensitize pituitary receptors (causing the initial flare), degarelix competitively blocks the receptor from the first dose. A depot formulation at the injection site provides sustained release. The trade-off is injection site reactions in approximately 40% of patients, substantially higher than with GnRH agonists.
What the evidence supports
FDA-approved with Phase III data demonstrating immediate testosterone suppression without flare. Castration achieved within 3 days in 96% of patients. Head-to-head trial versus leuprolide confirms non-inferiority for efficacy with the added benefit of eliminating the testosterone surge. The GnRH antagonist mechanism is pharmacologically distinct and clinically meaningful for patients at risk of symptom exacerbation from metastatic disease.
What is not yet established
Overall survival superiority over GnRH agonists has not been demonstrated. Whether the cardiovascular safety advantage suggested by some pooled analyses is a real clinical difference or a statistical artifact. Long-term comparison with the oral GnRH antagonist relugolix (Orgovyx). Optimal positioning in modern prostate cancer treatment algorithms alongside novel antiandrogens.
Research Evidence
The findings below cover the Phase III evidence and the clinical positioning against GnRH agonists.
Evidence by condition
Evidence dimensions across degarelix indications. Advanced prostate cancer and PSA suppression have deep clinical evidence supporting the FDA approval.
| Condition | Mechanism | Animal evidence | Human evidence | Replication |
|---|---|---|---|---|
| Advanced Prostate Cancer | ||||
| PSA Suppression |
Degarelix eliminates the testosterone flare that occurs with GnRH agonists. Castration-level testosterone (below 50 ng/dL) was achieved within 3 days in 96% of patients, compared to 2-4 weeks with leuprolide.
The no-flare advantage is clinically meaningful for patients with metastatic disease where testosterone surge could worsen bone pain, spinal cord compression, or urinary obstruction.
The Phase III CS21 trial demonstrated non-inferiority to leuprolide for sustained testosterone suppression over 12 months. Both drugs achieved comparable long-term castration rates.
Non-inferiority, not superiority, for the primary efficacy endpoint. The advantage is speed of onset and flare avoidance, not deeper suppression.
Injection site reactions occurred in approximately 40% of degarelix patients compared to less than 1% with GnRH agonists. This is the primary tolerability trade-off for the no-flare advantage.
Monthly subcutaneous abdominal injection required. No longer-duration depot formulation is available, unlike GnRH agonists which offer 1, 3, and 6-month options.
12 Human|162 Animal|26 Reviews
View all 144186 indexed studiesHow Degarelix Works
Degarelix is a synthetic decapeptide GnRH antagonist that competitively binds GnRH receptors on pituitary gonadotrophs, immediately blocking LH and FSH release without the initial hormonal surge caused by GnRH agonists.
GnRH agonists like triptorelin overstimulate and then shut down the hormone system. Causing a temporary testosterone surge before suppression. Degarelix takes the opposite approach: it directly blocks the GnRH receptor like putting a cap on a plug. No overstimulation, no surge, just immediate suppression. Testosterone drops to castration levels within 3 days.
For a more detailed view of the biology, here is what researchers have observed at the molecular level.
Degarelix is a synthetic decapeptide GnRH antagonist that competitively binds GnRH receptors on pituitary gonadotrophs, immediately blocking LH and FSH secretion. This produces rapid testosterone suppression to castrate levels (<50 ng/dL) within 3 days in 96% of patients, without the initial LH/testosterone flare seen with GnRH agonists. The drug forms a depot at the injection site, providing sustained release over the dosing interval.
What is Degarelix being studied for?
Researchers are studying Degarelix across several health conditions. Each condition below is labeled with the strength of evidence that exists for that specific use, not for Degarelix overall. This means a compound can have human studies for one condition but only animal data for another.
Advanced Prostate Cancer
·FDA ApprovedFDA-approved for advanced prostate cancer. Achieves castration-level testosterone within 3 days without the flare associated with GnRH agonists. Phase III data demonstrates non-inferiority to leuprolide.
Limitations: Overall survival advantage over GnRH agonists has not been demonstrated. Monthly injection only; no extended-release depot available. Injection site reactions in approximately 40% of patients.
PSA Suppression
·FDA ApprovedRapid PSA decline reflects immediate testosterone suppression. Both a treatment endpoint and monitoring biomarker for prostate cancer management.
Limitations: Whether faster PSA suppression translates to improved long-term survival outcomes compared to GnRH agonists is not established.
Safety and Regulatory Status
FDA Status: FDA-approved as Firmagon (degarelix acetate) for treatment of advanced prostate cancer.
Prescription status: Prescription-only in the United States. Administered by healthcare professionals.
Class context: Injectable GnRH antagonist. The oral GnRH antagonist relugolix (Orgovyx) provides an alternative approach to flare-free suppression.
The most notable side effect is injection site reactions in approximately 40% of patients, compared to less than 1% with GnRH agonists. Hot flashes, weight gain, and fatigue are expected consequences of androgen deprivation shared with all ADT drugs. The no-flare advantage is a genuine safety benefit for patients with symptomatic metastatic disease.
Questions and Comparisons
Questions the evidence raises for a Degarelix discussion.
Comparison and Related Research
Degarelix is most often compared with GnRH agonists and the oral GnRH antagonist relugolix. The comparisons below outline the key mechanistic and clinical differences.
Related compounds
Frequently Asked Questions
References
Each citation links to the original study on PubMed, the U.S. National Library of Medicine database.
- 1.Phase III CS21 trial comparing degarelix to leuprolide in 610 men with prostate cancer. Degarelix achieved faster testosterone suppression and maintained castrate levels over 12 months with comparable efficacy to leuprolide. This was the pivotal trial supporting FDA approval.Klotz L et al., 2008 in BJU Int. View on PubMed
- 2.Extension study that crossed patients from leuprolide to degarelix. Patients who switched experienced similar testosterone suppression, and the data suggested potential PSA-related benefits for those who crossed over to the GnRH antagonist.Crawford ED et al., 2011 in J Urol. View on PubMed
- 3.Cardiovascular safety analysis from the CS21 Phase III trial. The analysis found a lower rate of cardiovascular events in patients receiving degarelix compared to leuprolide, raising the possibility that GnRH antagonists may carry less cardiovascular risk than agonists.Smith MR et al., 2010 in J Urol. View on PubMed
- 4.Pooled analysis of PSA outcomes from the CS21 trial. Patients with higher baseline PSA levels who received degarelix showed lower rates of PSA failure compared to those receiving leuprolide, suggesting a potential advantage in higher-risk disease.Tombal B et al., 2010 in Eur Urol. View on PubMed
Medical Disclaimer
This content is for educational and informational purposes only and does not constitute medical advice. The information presented reflects published research as indexed by PSI and should not be used to make treatment decisions. Always consult a qualified healthcare provider before starting, stopping, or modifying any treatment.